40 completed, 5 active not recruiting, 4 unknown, 2 withdrawn. 17 Phase 2, 15 Phase 3, 13 Phase 4, 5 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 15, Unknown 1, Withdrawn 1 |
| Phase 3 | 15 | Completed 15 |
| Phase 4 | 13 | Completed 6, Active not recruiting 5, Unknown 2 |
| Phase 1 | 5 | Completed 5 |
| Not applicable | 2 | Recruiting 1, Withdrawn 1 |
Follow Microbial Collagenase: new trials by email Literature Review of Microbial Collagenase trials Research Report on Microbial Collagenase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease Collagenase Clostridium Histolyticum, RestoreX, Sildenafil - Peyronie Disease | Phase 4 | Active not recruiting | Charitable Union for the Research and Education of Peyronie's Disease | 40 | 2024-10-11 | 2026-08-26 |
| Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease Collagenase Clostridium Histolyticum, Storz Duolith LiSWT - Peyronie Disease, Erectile Dysfunction | Not applicable | Recruiting | Mayo Clinic | 60 | 2024-01-19 | 2026-10-16 |
| A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) Collagenase Clostridium Histolyticum (CCH), Placebo - Plantar Fasciitis | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 231 | 2024-01-03 | 2025-09-30 |
| Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease Collagenase Clostridium Histolyticum (CCH) - Peyronie Disease, Sexual Dysfunctions, Psychological | Phase 4 | Active not recruiting | University of Miami | 12 | 2023-10-02 | 2026-06-04 |
| Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction Collagenase Clostridium Histolyticum, Duolith SD1 T-TOP - Peyronie Disease, Penile Curvature | Not applicable | Withdrawn | Mayo Clinic | 2023-03-01 | 2023-10-10 | |
| Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders CCH administration, Control - Crossover to CCH, RestoreX - Peyronie's Disease | Phase 4 | Completed | Charitable Union for the Research and Education of Peyronie's Disease | 40 | 2021-09-20 | 2026-08-26 |
| Effectiveness of Splinting After Collagenase Injection Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex], Xiaflex + Hand-Based Custom Orthosis - Dupuytren Contracture, Dupuytren's Disease | Phase 3 | Completed | Foundation for Orthopaedic Research and Education | 80 | 2021-07-12 | 2025-02-26 |
| Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery - Peyronie's Disease | Phase 4 | Active not recruiting | Charitable Union for the Research and Education of Peyronie's Disease | 40 | 2020-12-30 | 2026-08-26 |
| CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques collagenase clostridium histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 35 | 2020-10-01 | 2022-09-28 |
| Clostridium Histolyticum Collagenase Injection for Urethral Disease Clostridium Histolyticum Collagenase, Saline - Urethral Stricture | Phase 2 | Completed | University of South Florida | 5 | 2020-05-22 | 2023-11-03 |
| Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Xiaflex®, Aveed - Peyronie's Disease (PD) | Phase 4 | Completed | Men's Health Boston | 20 | 2019-01-14 | 2020-12-31 |
| Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Xiaflex® 0.58 mg - Peyronie's Disease | Phase 4 | Unknown | Manhattan Medical Research Practice, PLLC | 20 | 2018-10-04 | 2018-12-07 |
| Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite) collagenase clostridium histolyticum (CCH) - Edematous Skin | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 64 | 2018-09-18 | 2023-09-07 |
| Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP CCH (collagenase clostridium histolyticum) - Edematous Fibrosclerotic Panniculopathy | Phase 1 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 12 | 2018-09-18 | 2020-10-06 |
| Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Fasciectomy, Collagenase Clostridium Histolyticum - Dupuytren Disease of Finger | Phase 4 | Active not recruiting | Region Skane | 60 | 2018-03-20 | 2025-04-16 |
| Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 158 | 2017-11-17 | 2020-12-29 |
| Trial Comparing Treatment Strategies in Dupuytren's Contracture Percutaneous needle fasciotomy (PNF), Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex], Limited fasciectomy (LF) - Dupuytren Contracture | Phase 4 | Active not recruiting | Tampere University | 302 | 2017-09-15 | 2026-04-29 |
| Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's collagenase injection, limited palmar fasciectomy - Dupuytren's Disease | Phase 3 | Completed | McMaster University | 22 | 2017-07-08 | 2023-07-18 |
| Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) Saline, EN3835 - Fibroids, Uterine, Leiomyoma | Phase 1 | Completed | Advance Biofactures Corporation | 15 | 2016-10-27 | 2019-07-10 |
| EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 259 | 2016-10-05 | 2020-11-24 |
Showing 20 of 52. Sign in to see all of them.
Dupuytren Contracture (16) · Penile Induration (14) · Cellulite (8) · Bursitis (3) · Contracture (3) · Erectile Dysfunction (2) · Lipoma (2) · Connective Tissue Diseases (1) · Cutis Laxa (1) · Fasciitis, Plantar (1) · Genital Diseases, Male (1) · Hypogonadism (1) · Leiomyoma (1) · Recurrence (1) · Sexual Dysfunctions, Psychological (1)
Endo USA Inc., a Keenova Therapeutics Company (26) · Charitable Union for the Research and Education of Peyronie's Disease (3) · Stony Brook University (3) · Mayo Clinic (2) · Advance Biofactures Corporation (1) · Asahi Kasei Therapeutics Corporation (1) · Foundation for Orthopaedic Research and Education (1) · Gerut, Zachary, M.D. (1) · Hospital for Special Surgery, New York (1) · Indiana Hand to Shoulder Center (1) · Manhattan Medical Research Practice, PLLC (1) · McMaster University (1) · Men's Health Boston (1) · Region Skane (1) · Sheba Medical Center (1)
United States (41) · Australia (7) · Canada (3) · Sweden (3) · United Kingdom (3) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · New Zealand (1) · Norway (1) · Spain (1)
Veronica Urdaneta, MD (5) · Gregory J. Kaufman, MD (3) · Veronica Urdaneta, MD MPH (3) · Veronica Urdaneta, MD, MPPH (3) · Gregory Kaufman, MD (2) · Landon Trost, MD (2) · Marie A Badalamente, PhD (2) · Abraham Morgentaler, MD (1) · Achilleas Thoma, MD MSc FRCSC (1) · Aleksi RP Reito, M.D., Ph.D., adjunct professor (1) · Antti OV Malmivaara, M.D., Ph.D., adjunct professor (1) · David Hernandez (1) · Edward Wang, MD (1) · George Omburo (1) · Hannu Kautiainen, MSc (1)
PMID 19726771, PMID 26199168, PMID 15541123, PMID 17437780, PMID 17617144, PMID 17983892, PMID 21315996, PMID 21967070, PMID 23376148, PMID 24745607, PMID 25388099, PMID 26126692, PMID 26491251, PMID 27313184, PMID 28854973, PMID 28974406, PMID 30808670, PMID 34323413, PMID 38346307, PMID 41334972, PMID 9679876